MTAP and malignant mesothelioma: Sun et al further highlighted the role of PAX8 immunohistochemistry as a sensitive and specific marker for distinguishing WDPMT from malignant mesotheliomas, aiding in the accurate diagnosis and appropriate management of the disease.[18] The absence of BAP1 and MTAP/CDKN2A expression in WDPMT, as shown by Hassan et al, also plays a crucial role in differentiating it from mesothelioma in situ, which has a different clinical course and potential for malignancy.[20]